nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—Risedronate—osteoporosis	0.648	1	CbGbCtD
Tafluprost—Exacerbation of asthma—Etidronic acid—osteoporosis	0.0143	0.0473	CcSEcCtD
Tafluprost—Exacerbation of asthma—Estropipate—osteoporosis	0.0124	0.0409	CcSEcCtD
Tafluprost—Exacerbation of asthma—Alendronate—osteoporosis	0.0122	0.0403	CcSEcCtD
Tafluprost—Exacerbation of asthma—Ibandronate—osteoporosis	0.0118	0.0392	CcSEcCtD
Tafluprost—Exacerbation of asthma—Risedronate—osteoporosis	0.00976	0.0323	CcSEcCtD
Tafluprost—Uveitis—Alendronate—osteoporosis	0.00909	0.0301	CcSEcCtD
Tafluprost—Uveitis—Ibandronate—osteoporosis	0.00885	0.0293	CcSEcCtD
Tafluprost—Exacerbation of asthma—Zoledronate—osteoporosis	0.00848	0.0281	CcSEcCtD
Tafluprost—Exacerbation of asthma—Conjugated Estrogens—osteoporosis	0.00816	0.027	CcSEcCtD
Tafluprost—Iritis—Ibandronate—osteoporosis	0.00814	0.0269	CcSEcCtD
Tafluprost—Uveitis—Risedronate—osteoporosis	0.00729	0.0241	CcSEcCtD
Tafluprost—Uveitis—Pamidronate—osteoporosis	0.00693	0.023	CcSEcCtD
Tafluprost—Iritis—Risedronate—osteoporosis	0.0067	0.0222	CcSEcCtD
Tafluprost—Exacerbation of asthma—Estradiol—osteoporosis	0.00653	0.0216	CcSEcCtD
Tafluprost—Common cold—Estradiol—osteoporosis	0.00653	0.0216	CcSEcCtD
Tafluprost—Endophthalmitis—Ibandronate—osteoporosis	0.0065	0.0215	CcSEcCtD
Tafluprost—Iritis—Pamidronate—osteoporosis	0.00637	0.0211	CcSEcCtD
Tafluprost—Uveitis—Zoledronate—osteoporosis	0.00633	0.021	CcSEcCtD
Tafluprost—Iritis—Zoledronate—osteoporosis	0.00582	0.0193	CcSEcCtD
Tafluprost—PTGFR—Small Ligand GPCRs—CNR2—osteoporosis	0.00567	0.114	CbGpPWpGaD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00559	0.113	CbGpPWpGaD
Tafluprost—Eye pruritus—Pamidronate—osteoporosis	0.00542	0.0179	CcSEcCtD
Tafluprost—Endophthalmitis—Risedronate—osteoporosis	0.00535	0.0177	CcSEcCtD
Tafluprost—Ocular hyperaemia—Zoledronate—osteoporosis	0.00472	0.0156	CcSEcCtD
Tafluprost—Endophthalmitis—Zoledronate—osteoporosis	0.00465	0.0154	CcSEcCtD
Tafluprost—Ocular hyperaemia—Estradiol—osteoporosis	0.00364	0.012	CcSEcCtD
Tafluprost—Endophthalmitis—Estradiol—osteoporosis	0.00358	0.0119	CcSEcCtD
Tafluprost—Eyelid oedema—Estradiol—osteoporosis	0.00338	0.0112	CcSEcCtD
Tafluprost—Cataract—Ibandronate—osteoporosis	0.00325	0.0108	CcSEcCtD
Tafluprost—Photophobia—Calcitriol—osteoporosis	0.00284	0.00941	CcSEcCtD
Tafluprost—Cataract—Risedronate—osteoporosis	0.00268	0.00886	CcSEcCtD
Tafluprost—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—osteoporosis	0.00247	0.0498	CbGpPWpGaD
Tafluprost—Dry eye—Risedronate—osteoporosis	0.00235	0.00779	CcSEcCtD
Tafluprost—Asthma—Etidronic acid—osteoporosis	0.00234	0.00774	CcSEcCtD
Tafluprost—Cataract—Zoledronate—osteoporosis	0.00232	0.0077	CcSEcCtD
Tafluprost—Asthma—Estropipate—osteoporosis	0.00202	0.0067	CcSEcCtD
Tafluprost—Nasopharyngitis—Ibandronate—osteoporosis	0.00201	0.00665	CcSEcCtD
Tafluprost—Eye irritation—Estradiol—osteoporosis	0.002	0.00661	CcSEcCtD
Tafluprost—Asthma—Alendronate—osteoporosis	0.00199	0.0066	CcSEcCtD
Tafluprost—Nasopharyngitis—Calcitriol—osteoporosis	0.00197	0.00651	CcSEcCtD
Tafluprost—Asthma—Ibandronate—osteoporosis	0.00194	0.00642	CcSEcCtD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00182	0.0367	CbGpPWpGaD
Tafluprost—Eye pain—Zoledronate—osteoporosis	0.00178	0.00589	CcSEcCtD
Tafluprost—Urinary tract infection—Raloxifene—osteoporosis	0.0017	0.00562	CcSEcCtD
Tafluprost—Urinary tract infection—Ibandronate—osteoporosis	0.00168	0.00557	CcSEcCtD
Tafluprost—Nasopharyngitis—Risedronate—osteoporosis	0.00165	0.00548	CcSEcCtD
Tafluprost—Urinary tract infection—Calcitriol—osteoporosis	0.00165	0.00545	CcSEcCtD
Tafluprost—Rhinitis—Estropipate—osteoporosis	0.00162	0.00538	CcSEcCtD
Tafluprost—Asthma—Risedronate—osteoporosis	0.0016	0.00529	CcSEcCtD
Tafluprost—Dry eye—Estradiol—osteoporosis	0.00158	0.00522	CcSEcCtD
Tafluprost—Rhinitis—Raloxifene—osteoporosis	0.00157	0.00521	CcSEcCtD
Tafluprost—Nasopharyngitis—Pamidronate—osteoporosis	0.00157	0.00521	CcSEcCtD
Tafluprost—Eye disorder—Estropipate—osteoporosis	0.00151	0.00501	CcSEcCtD
Tafluprost—Eye disorder—Ibandronate—osteoporosis	0.00145	0.0048	CcSEcCtD
Tafluprost—Nasopharyngitis—Zoledronate—osteoporosis	0.00144	0.00476	CcSEcCtD
Tafluprost—Pruritus—Calcium Acetate—osteoporosis	0.00143	0.00475	CcSEcCtD
Tafluprost—Urinary tract infection—Ethinyl Estradiol—osteoporosis	0.00142	0.00471	CcSEcCtD
Tafluprost—PTGFR—G alpha (q) signalling events—MGLL—osteoporosis	0.00141	0.0285	CbGpPWpGaD
Tafluprost—Asthma—Zoledronate—osteoporosis	0.00139	0.0046	CcSEcCtD
Tafluprost—Urinary tract infection—Risedronate—osteoporosis	0.00139	0.00459	CcSEcCtD
Tafluprost—Asthma—Conjugated Estrogens—osteoporosis	0.00134	0.00443	CcSEcCtD
Tafluprost—Urinary tract infection—Pamidronate—osteoporosis	0.00132	0.00436	CcSEcCtD
Tafluprost—Rhinitis—Ethinyl Estradiol—osteoporosis	0.00132	0.00436	CcSEcCtD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—NFATC1—osteoporosis	0.0013	0.0262	CbGpPWpGaD
Tafluprost—Rhinitis—Risedronate—osteoporosis	0.00128	0.00425	CcSEcCtD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00126	0.0255	CbGpPWpGaD
Tafluprost—Cough—Estropipate—osteoporosis	0.00123	0.00407	CcSEcCtD
Tafluprost—Eye disorder—Ethinyl Estradiol—osteoporosis	0.00123	0.00406	CcSEcCtD
Tafluprost—Rhinitis—Pamidronate—osteoporosis	0.00122	0.00404	CcSEcCtD
Tafluprost—Urinary tract infection—Zoledronate—osteoporosis	0.0012	0.00398	CcSEcCtD
Tafluprost—Eye disorder—Risedronate—osteoporosis	0.0012	0.00396	CcSEcCtD
Tafluprost—Cough—Raloxifene—osteoporosis	0.00119	0.00395	CcSEcCtD
Tafluprost—Eye disorder—Pamidronate—osteoporosis	0.00114	0.00376	CcSEcCtD
Tafluprost—Nervous system disorder—Estropipate—osteoporosis	0.00113	0.00374	CcSEcCtD
Tafluprost—PTGS2—Selenium Micronutrient Network—PRDX3—osteoporosis	0.00111	0.0224	CbGpPWpGaD
Tafluprost—Nasopharyngitis—Estradiol—osteoporosis	0.00111	0.00367	CcSEcCtD
Tafluprost—Nervous system disorder—Raloxifene—osteoporosis	0.00109	0.00362	CcSEcCtD
Tafluprost—Nervous system disorder—Ibandronate—osteoporosis	0.00108	0.00358	CcSEcCtD
Tafluprost—Rhinitis—Conjugated Estrogens—osteoporosis	0.00107	0.00355	CcSEcCtD
Tafluprost—Asthma—Estradiol—osteoporosis	0.00107	0.00354	CcSEcCtD
Tafluprost—Eye disorder—Zoledronate—osteoporosis	0.00104	0.00344	CcSEcCtD
Tafluprost—Eye disorder—Conjugated Estrogens—osteoporosis	0.001	0.00331	CcSEcCtD
Tafluprost—Cough—Ethinyl Estradiol—osteoporosis	0.000997	0.0033	CcSEcCtD
Tafluprost—Cough—Risedronate—osteoporosis	0.000972	0.00322	CcSEcCtD
Tafluprost—Pruritus—Etidronic acid—osteoporosis	0.000941	0.00312	CcSEcCtD
Tafluprost—Urinary tract infection—Estradiol—osteoporosis	0.000927	0.00307	CcSEcCtD
Tafluprost—Cough—Pamidronate—osteoporosis	0.000924	0.00306	CcSEcCtD
Tafluprost—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000915	0.00303	CcSEcCtD
Tafluprost—Vision blurred—Zoledronate—osteoporosis	0.000912	0.00302	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—CALCR—osteoporosis	0.000897	0.0181	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTH1R—osteoporosis	0.000897	0.0181	CbGpPWpGaD
Tafluprost—Nervous system disorder—Risedronate—osteoporosis	0.000892	0.00295	CcSEcCtD
Tafluprost—Vision blurred—Conjugated Estrogens—osteoporosis	0.000878	0.00291	CcSEcCtD
Tafluprost—Rhinitis—Estradiol—osteoporosis	0.000859	0.00284	CcSEcCtD
Tafluprost—Nervous system disorder—Pamidronate—osteoporosis	0.000848	0.00281	CcSEcCtD
Tafluprost—Cough—Zoledronate—osteoporosis	0.000844	0.00279	CcSEcCtD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	0.00084	0.0169	CbGpPWpGaD
Tafluprost—Headache—Etidronic acid—osteoporosis	0.000833	0.00276	CcSEcCtD
Tafluprost—Pruritus—Estropipate—osteoporosis	0.000814	0.0027	CcSEcCtD
Tafluprost—Cough—Conjugated Estrogens—osteoporosis	0.000813	0.00269	CcSEcCtD
Tafluprost—Dyspnoea—Risedronate—osteoporosis	0.000811	0.00268	CcSEcCtD
Tafluprost—Pruritus—Alendronate—osteoporosis	0.000802	0.00265	CcSEcCtD
Tafluprost—Eye disorder—Estradiol—osteoporosis	0.0008	0.00265	CcSEcCtD
Tafluprost—Pruritus—Ibandronate—osteoporosis	0.000781	0.00258	CcSEcCtD
Tafluprost—Nervous system disorder—Zoledronate—osteoporosis	0.000774	0.00256	CcSEcCtD
Tafluprost—Dyspnoea—Pamidronate—osteoporosis	0.000771	0.00255	CcSEcCtD
Tafluprost—Pruritus—Calcitriol—osteoporosis	0.000764	0.00253	CcSEcCtD
Tafluprost—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000746	0.00247	CcSEcCtD
Tafluprost—Headache—Estropipate—osteoporosis	0.000721	0.00239	CcSEcCtD
Tafluprost—Headache—Alendronate—osteoporosis	0.00071	0.00235	CcSEcCtD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000704	0.0142	CbGpPWpGaD
Tafluprost—Dyspnoea—Zoledronate—osteoporosis	0.000704	0.00233	CcSEcCtD
Tafluprost—Headache—Raloxifene—osteoporosis	0.000698	0.00231	CcSEcCtD
Tafluprost—Headache—Ibandronate—osteoporosis	0.000691	0.00229	CcSEcCtD
Tafluprost—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000678	0.00224	CcSEcCtD
Tafluprost—Headache—Calcitriol—osteoporosis	0.000677	0.00224	CcSEcCtD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	0.000662	0.0133	CbGpPWpGaD
Tafluprost—Pruritus—Ethinyl Estradiol—osteoporosis	0.00066	0.00218	CcSEcCtD
Tafluprost—Cough—Estradiol—osteoporosis	0.000651	0.00215	CcSEcCtD
Tafluprost—Pruritus—Risedronate—osteoporosis	0.000643	0.00213	CcSEcCtD
Tafluprost—Pruritus—Pamidronate—osteoporosis	0.000612	0.00202	CcSEcCtD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000603	0.0121	CbGpPWpGaD
Tafluprost—Nervous system disorder—Estradiol—osteoporosis	0.000597	0.00198	CcSEcCtD
Tafluprost—Headache—Ethinyl Estradiol—osteoporosis	0.000584	0.00193	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—COL1A2—osteoporosis	0.000584	0.0118	CbGpPWpGaD
Tafluprost—Headache—Risedronate—osteoporosis	0.00057	0.00189	CcSEcCtD
Tafluprost—Pruritus—Zoledronate—osteoporosis	0.000559	0.00185	CcSEcCtD
Tafluprost—Dyspnoea—Estradiol—osteoporosis	0.000542	0.0018	CcSEcCtD
Tafluprost—Headache—Pamidronate—osteoporosis	0.000541	0.00179	CcSEcCtD
Tafluprost—Pruritus—Conjugated Estrogens—osteoporosis	0.000538	0.00178	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—WNT1—osteoporosis	0.00053	0.0107	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CALCR—osteoporosis	0.000507	0.0102	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTH1R—osteoporosis	0.000507	0.0102	CbGpPWpGaD
Tafluprost—Headache—Zoledronate—osteoporosis	0.000495	0.00164	CcSEcCtD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	0.000494	0.00996	CbGpPWpGaD
Tafluprost—Headache—Conjugated Estrogens—osteoporosis	0.000476	0.00158	CcSEcCtD
Tafluprost—PTGFR—GPCR ligand binding—PTH—osteoporosis	0.000471	0.00949	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTH1R—osteoporosis	0.00046	0.00927	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CALCR—osteoporosis	0.00046	0.00927	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CNR2—osteoporosis	0.000459	0.00925	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000453	0.00912	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—WNT1—osteoporosis	0.000432	0.0087	CbGpPWpGaD
Tafluprost—Pruritus—Estradiol—osteoporosis	0.00043	0.00143	CcSEcCtD
Tafluprost—PTGFR—GPCR downstream signaling—MGLL—osteoporosis	0.000403	0.00811	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.000397	0.008	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTHLH—osteoporosis	0.000391	0.00787	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—TNF—osteoporosis	0.00039	0.00786	CbGpPWpGaD
Tafluprost—Headache—Estradiol—osteoporosis	0.000381	0.00126	CcSEcCtD
Tafluprost—PTGFR—Signaling by GPCR—MGLL—osteoporosis	0.000366	0.00737	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CALCA—osteoporosis	0.000344	0.00692	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—osteoporosis	0.000315	0.00635	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000311	0.00627	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD2—osteoporosis	0.000302	0.00609	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SOST—osteoporosis	0.000301	0.00606	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000295	0.00593	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	0.000288	0.00581	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CALCR—osteoporosis	0.000272	0.00548	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTH1R—osteoporosis	0.000272	0.00548	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	0.000268	0.00541	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTH—osteoporosis	0.000266	0.00536	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000266	0.00536	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000264	0.00531	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CNR2—osteoporosis	0.00026	0.00523	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.00025	0.00503	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTH—osteoporosis	0.000242	0.00487	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000236	0.00476	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CNR2—osteoporosis	0.000236	0.00475	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—WNT1—osteoporosis	0.000222	0.00446	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTHLH—osteoporosis	0.000221	0.00445	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MGLL—osteoporosis	0.000216	0.00435	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LRP5—osteoporosis	0.000211	0.00425	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.00021	0.00422	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	0.000207	0.00416	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LRP6—osteoporosis	0.000202	0.00406	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTHLH—osteoporosis	0.0002	0.00404	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—LEP—osteoporosis	0.000196	0.00394	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CALCA—osteoporosis	0.000194	0.00391	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000194	0.00391	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	0.000192	0.00388	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000189	0.00381	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	0.00018	0.00363	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—POMC—osteoporosis	0.00018	0.00362	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CALCA—osteoporosis	0.000176	0.00355	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TLN1—osteoporosis	0.00017	0.00343	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	0.000158	0.00318	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000151	0.00305	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—P4HB—osteoporosis	0.000147	0.00296	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTH—osteoporosis	0.000143	0.00288	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RAP1A—osteoporosis	0.00014	0.00283	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PKM—osteoporosis	0.00014	0.00282	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SOST—osteoporosis	0.00014	0.00282	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CNR2—osteoporosis	0.000139	0.0028	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000139	0.00279	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADCY5—osteoporosis	0.000138	0.00278	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NFATC1—osteoporosis	0.000137	0.00276	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—DKK1—osteoporosis	0.000136	0.00274	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PGLS—osteoporosis	0.000133	0.00268	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ANTXR2—osteoporosis	0.000133	0.00268	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—WNT1—osteoporosis	0.000131	0.00264	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000129	0.00259	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	0.000128	0.00257	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGA—osteoporosis	0.000127	0.00256	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000127	0.00256	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADCY5—osteoporosis	0.000126	0.00253	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	0.000125	0.00251	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—BMP2—osteoporosis	0.000118	0.00238	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTHLH—osteoporosis	0.000118	0.00238	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PKM—osteoporosis	0.000117	0.00236	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—FDPS—osteoporosis	0.000117	0.00236	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGB—osteoporosis	0.000116	0.00233	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	0.000115	0.00231	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GSN—osteoporosis	0.000113	0.00228	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PSMA5—osteoporosis	0.000112	0.00225	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PSMA2—osteoporosis	0.000112	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPD2—osteoporosis	0.000111	0.00224	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PGLS—osteoporosis	0.000111	0.00224	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.00011	0.00222	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CALCA—osteoporosis	0.000104	0.0021	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ATIC—osteoporosis	0.000102	0.00205	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PNP—osteoporosis	0.000102	0.00205	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—POMC—osteoporosis	0.000102	0.00205	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LRP5—osteoporosis	9.83e-05	0.00198	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—osteoporosis	9.72e-05	0.00196	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	9.7e-05	0.00195	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KL—osteoporosis	9.46e-05	0.00191	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LRP6—osteoporosis	9.4e-05	0.00189	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	9.24e-05	0.00186	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—POMC—osteoporosis	9.23e-05	0.00186	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—osteoporosis	9.06e-05	0.00182	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPL24—osteoporosis	9.03e-05	0.00182	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LTF—osteoporosis	9.03e-05	0.00182	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6R—osteoporosis	9.01e-05	0.00181	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CA2—osteoporosis	8.65e-05	0.00174	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—OXCT1—osteoporosis	8.65e-05	0.00174	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MGLL—osteoporosis	8.43e-05	0.0017	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.95e-05	0.0016	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ACP5—osteoporosis	7.83e-05	0.00158	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADCY5—osteoporosis	7.41e-05	0.00149	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—osteoporosis	7.31e-05	0.00147	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TPI1—osteoporosis	7.28e-05	0.00147	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SPP1—osteoporosis	7.17e-05	0.00144	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—IDH2—osteoporosis	7.17e-05	0.00144	CbGpPWpGaD
Tafluprost—PTGS2—Disease—P4HB—osteoporosis	6.84e-05	0.00138	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP27A1—osteoporosis	6.74e-05	0.00136	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GAPDH—osteoporosis	6.72e-05	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	6.62e-05	0.00133	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	6.6e-05	0.00133	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ACP5—osteoporosis	6.56e-05	0.00132	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IRS2—osteoporosis	6.49e-05	0.00131	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.47e-05	0.0013	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NFATC1—osteoporosis	6.38e-05	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LEP—osteoporosis	6.35e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DKK1—osteoporosis	6.33e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.16e-05	0.00124	CbGpPWpGaD
Tafluprost—PTGS2—Disease—WNT1—osteoporosis	6.1e-05	0.00123	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TPI1—osteoporosis	6.1e-05	0.00123	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ESR1—osteoporosis	6.06e-05	0.00122	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGA—osteoporosis	5.93e-05	0.0012	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—P4HB—osteoporosis	5.73e-05	0.00115	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IRS1—osteoporosis	5.66e-05	0.00114	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GAPDH—osteoporosis	5.63e-05	0.00113	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—RAP1A—osteoporosis	5.48e-05	0.0011	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—POMC—osteoporosis	5.45e-05	0.0011	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6R—osteoporosis	5.32e-05	0.00107	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ENO1—osteoporosis	5.29e-05	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF1—osteoporosis	5.25e-05	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PSMA2—osteoporosis	5.21e-05	0.00105	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PSMA5—osteoporosis	5.21e-05	0.00105	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CALCA—osteoporosis	4.86e-05	0.000978	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.78e-05	0.000962	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ENO1—osteoporosis	4.43e-05	0.000892	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KL—osteoporosis	4.41e-05	0.000888	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PSMA2—osteoporosis	4.36e-05	0.000879	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PSMA5—osteoporosis	4.36e-05	0.000879	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—osteoporosis	4.01e-05	0.000808	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP19A1—osteoporosis	3.54e-05	0.000713	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ADCY5—osteoporosis	3.45e-05	0.000696	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTHFR—osteoporosis	3.18e-05	0.00064	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—osteoporosis	3.15e-05	0.000635	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFB1—osteoporosis	3.14e-05	0.000633	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IRS2—osteoporosis	3.02e-05	0.000609	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ADCY5—osteoporosis	2.89e-05	0.000583	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX1—osteoporosis	2.88e-05	0.000581	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTHFR—osteoporosis	2.66e-05	0.000536	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IRS1—osteoporosis	2.64e-05	0.000532	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6R—osteoporosis	2.48e-05	0.000499	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—osteoporosis	2.37e-05	0.000477	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—POMC—osteoporosis	2.13e-05	0.000429	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—osteoporosis	1.47e-05	0.000296	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFB1—osteoporosis	1.47e-05	0.000295	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—osteoporosis	1.1e-05	0.000222	CbGpPWpGaD
